Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Alnylam Pharmaceuticals ): The pharma company has six commercial products, three of which received a breakthrough designation.
Source: https://investorplace.com/2023/03/3-growth-stocks-that-could-disrupt-the-healthcare-industry/
Amalgamated Bank boosted its stake in Alnylam Pharmaceuticals, Inc. () by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.
And you mentioned with some of these modalities, you mentioned siRNA, and I know you guys alongside your partner Alnylam recently reported proof of principle data from an APP targeted RNAi.
As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -6.46 EPS for the current year.
Bank of New York Mellon Corp’s holdings in Alnylam Pharmaceuticals were worth $113,517,000 as of its most recent SEC filing.
Clarius Group LLC acquired a new position in shares of Alnylam Pharmaceuticals, Inc. () in the 3rd quarter, reports.
Finally, 1832 Asset Management L.P. acquired a new position in Alnylam Pharmaceuticals during the 1st quarter worth approximately $88,000.
Finally, Canaccord Genuity Group lowered their target price on Alnylam Pharmaceuticals from $310.00 to $291.00 and set a “buy” rating on the stock in a research note on Friday, February 24th.
Finally, Harvest Fund Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $95,000.
In related news, CEO sold 7,615 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, April 27th.
Morgan Stanley cut their target price on Alnylam Pharmaceuticals from $220.00 to $210.00 and set an “equal weight” rating for the company in a research note on Friday, October 28th.
Morgan Stanley decreased their price target on Alnylam Pharmaceuticals from $220.00 to $210.00 and set an “equal weight” rating for the company in a report on Friday, October 28th.
Needham & Company LLC restated a “buy” rating and issued a $240.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, February 24th.
Norges Bank purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $240,703,000.
Oppenheimer dropped their price target on Alnylam Pharmaceuticals from $256.00 to $249.00 and set an “outperform” rating on the stock in a research note on Friday, February 24th.
Price T Rowe Associates Inc. MD lifted its position in shares of Alnylam Pharmaceuticals by 3.0% in the second quarter.
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through sold 4,057 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, August 4th.
V Square Quantitative Management LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $53,000.